Qwixel Therapeutics LLC

University of California

Nammi Therapeutics, Inc.

Alex Vasuthasawat

Sherie L Morrison

David Stover

Kham Trinh

George Ayoub

Kham M Trinh

John M Timmerman

Reiko King

Patricia Young

Sherie Morrison

In various embodiments methods are provided that involve the use of antibody-interferon (Ab-IFN) fusion proteins to boost the cancer-fighting capacity of adoptive T cell therapies (ACT), including any T cells that are manipulated and grown outside the body, then returned to the patient with the goal of having the infused T cells home to sites of tumor and destroy the cancer in an immunologic attack. Illustrative, but non-limiting, adoptive T cell therapies include chimeric antigen receptor (CAR) T cells, tumor-infiltrating lymphocytes (TILs), virus-specific T cells, and T cell receptor transgenic T cells.

Antibody-interferon fusion proteins for enhancing adoptive T cell therapies for the treatment of cancer

Fusion Protein compositions comprising masked IFNs and methods of making masked IFNs are disclosed herein. Consequently, the masked IFNs can be fused to a Mab or binding fragment thereof and be administered to patients as a therapeutic modality and provide a method of treating cancer, immunological disorders and other disease.

Fusion protein composition(s) comprising masked type i interferons (IFNA and IFNB) for use in the treatment of cancer and methods thereof

Fusion protein composition(s) comprising masked type I interferons (IFNA and IFNB) for use in the treatment of cancer and methods thereof

Growing community of inventors

Los Angeles, CA, United States of America

Alex Vasuthasawat